FDA Warns Indian OTC Facility for Quality Violations

Drug Industry Daily
A A
The FDA issued a warning letter to Wilson Medicine Company citing serious quality problems found during a Feb. 26-March 1 inspection of its OTC manufacturing facility in Nandore, India.

To View This Article:

Login

Subscribe To Drug Industry Daily